Key result
Indomethacin tocolysis shows no impact on fetal Mod-MPI compared to normal pregnancies.
Why the study?
Does indomethacin tocolytic therapy affect fetal cardiac function (Mod-MPI) and hemodynamics in pregnant women with threatened preterm labor?
Observational (n=114)
No
Does indomethacin tocolytic therapy affect fetal cardiac function (Mod-MPI) and hemodynamics in pregnant women with threatened preterm labor?
Short-term indomethacin tocolytic therapy does not negatively affect fetal global cardiac function as measured by Mod-MPI, despite causing transient tricuspid regurgitation and altered umbilical artery pulsatility in some fetuses.
Answers are grounded in this paper and cite their sources.
Supports short-term indomethacin with Mod-MPI monitoring in threatened preterm labor; extends observational safety data but leaves open randomized confirmation.
BACKGROUND: Indomethacin is one of the most effective and widely used tocolytic agents for treating threatened preterm labor and prolonging pregnancy. Nonetheless, data on its fetal effects, particularly regarding cardiac functions, remain limited. The primary aim of this study was to evaluate the effects of indomethacin treatment on fetal cardiac structures, the modified myocardial performance index (Mod-MPI), and hemodynamic parameters to establish evidence-based monitoring recommendations in cases of threatened preterm labor. METHODS: In this prospective study of 114 pregnant women, 57 cases diagnosed with threatened preterm birth received indomethacin tocolytic therapy, while 57 controls had uneventful pregnancies. Demographic characteristics, perinatal outcomes, Doppler measurements, cardiac structural measurements, Mod-MPI, and tricuspid regurgitation were compared between groups. RESULTS: Doppler analysis revealed no significant differences except for umbilical artery pulsatility index, which was elevated in the indomethacin group (0.941 ± 0.160 vs. 0.869 ± 0.171, p = 0.023) due to vasoconstrictive effects from prostaglandin synthesis inhibition. Isovolumetric contraction and relaxation times were lower in the indomethacin group (42.3 ± 0.5 vs. 47.2 ± 2.7, p = 0.020; 49.3 ± 1.9 vs. 48.2 ± 1.8, p = 0.030). However, Mod-MPI did not differ significantly between the groups (0.464 ± 0.11 vs. 0.44 ± 0.09, p = 0.349). Although tricuspid regurgitation was observed in 14 of 57 fetuses (24.6%) exposed to indomethacin, perinatal outcomes were not significantly different. CONCLUSIONS: Indomethacin treatment does not negatively affect fetal cardiac function or Mod-MPI. When tricuspid regurgitation occurs, increased monitoring is recommended rather than treatment cessation if other parameters remain stable.
No takes yet. Share an insight, caveat, or question.
Boza et al. (2025) conducted an observational in Threatened preterm labor (n=114). Indomethacin vs. Uneventful pregnancies was evaluated on Modified myocardial performance index (Mod-MPI) (p=0.349). Indomethacin treatment for threatened preterm labor did not affect the fetal modified myocardial performance index compared to normal pregnancies.
Synapse has enriched 10 related papers. Consider them for comparative context: